Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy

Sarepta Therapeutics' shares continued to decline after the company bowed to FDA pressure, announcing a temporary pause on all shipments of its gene therapy, Elevidys, for Duchenne's muscular dystrophy. This reversal from an initial refusal follows multiple patient deaths, including two linked to Elevidys, and is seen by analysts as crucial for preserving Sarepta's relationship with the FDA, potentially leading to a 3-6 month distribution halt for the first U.S.-approved therapy of its kind.

Analysis

Sarepta Therapeutics (SRPT) is facing significant headwinds, evidenced by its declining share price and a strongly negative sentiment score (-0.9). The core issue is the company's decision to temporarily halt shipments of its key gene therapy, Elevidys, after initially defying a Food and Drug Administration (FDA) request. This highly unusual confrontation with the regulator was prompted by multiple patient deaths, including two linked to Elevidys' known side effect of acute liver injury. While the company's reversal is viewed by analysts as a necessary step to avoid irreparably damaging its relationship with the FDA, it creates substantial near-term uncertainty. The pause is estimated by TD Cowen to last three to six months, directly impacting the company's best-selling product and compounding existing pressures that have already led to hundreds of layoffs. The events underscore the high-stakes risk profile of Sarepta, whose first-in-class therapy for Duchenne's muscular dystrophy is now under intense regulatory scrutiny, jeopardizing a critical revenue stream.

Key Decisions for Investors

• Investors should anticipate continued share price volatility and a significant revenue shortfall in the coming quarters, given the estimated three-to-six-month halt on Elevidys shipments.
• The company's initial defiance of the FDA introduces a material governance risk; therefore, monitoring the tenor of future communications with the regulator will be critical for assessing long-term viability.
• The primary catalyst for the stock will be the outcome of the FDA's safety review, and positions should be managed with close attention to any news regarding the investigation into patient deaths and the potential conditions for resuming Elevidys distribution.